mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth, metabolism, and survival.
• mTOR signaling is frequently dysregulated in various cancers, making it a target for cancer therapy.
• Existing mTOR kinase inhibitors targeting both mTORC1 and mTORC2 have shown limited clinical success.

Purpose of the Study:

• To investigate the reasons behind cancer insensitivity or unresponsiveness to mTOR-targeted therapies.
• To explore novel mechanisms contributing to resistance against mTOR inhibitors.
• To identify new strategies for improving the efficacy of mTOR inhibitors in cancer treatment.

Main Methods:

• Review of existing literature on mTOR signaling in cancer.
• Analysis of recent findings on resistance mechanisms to mTOR inhibitors.
• Exploration of the roles of GSK3 and PD-L1 in mediating cancer cell response.

Main Results:

• Cancer cells can develop resistance to mTOR inhibitors through various signaling pathways, including PI3K/Akt, MEK/ERK, and Mnk/eIF4E.
• Glycogen synthase kinase 3 (GSK3) plays a key role in mediating cancer cell response to mTOR inhibitors.
• mTORC1 inhibition can lead to increased expression of programmed death-ligand 1 (PD-L1) in cancer cells.

Conclusions:

• Understanding resistance mechanisms, such as the involvement of GSK3 and PD-L1 upregulation, is crucial for optimizing mTOR inhibitor therapy.
• New findings offer opportunities for rationally utilizing mTOR inhibitors in combination therapies.
• Further research into complex mTOR networks may lead to more effective therapeutic strategies against cancer.